View Older Stories View More Recent Stories

Dec 2, 2018 12:00PM Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting
Dec 1, 2018 12:00PM Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting
Nov 26, 2018 08:00AM Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
Nov 16, 2018 10:53AM Seattle Genetics (SGEN) Reports FDA Approval of ADCETRIS (Brentuximab Vedotin) in Combination with Chemotherapy
Nov 16, 2018 10:52AM Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-
Nov 15, 2018 08:02AM Seattle Genetics (SGEN) Announces FDA Granted Breakthrough Therapy Designation to ADCETRIS for Frontline Peripheral T-Cell Lymphomas
Nov 15, 2018 08:00AM FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas
Nov 14, 2018 08:06AM Seattle Genetics (SGEN) Commences Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma
Nov 14, 2018 08:00AM Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma
Nov 6, 2018 08:00AM Seattle Genetics to Present at the Credit Suisse 27th Annual Healthcare Conference
Nov 5, 2018 08:05AM Seattle Genetics (SGEN) Reports Supplemental Biologics License Application Submission for ADCETRIS (Brentuximab Vedotin)
Nov 5, 2018 08:00AM Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
Nov 1, 2018 04:05PM Seattle Genetics Announces More Than 30 Presentations at ASH 2018 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Program
Oct 26, 2018 08:00AM Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) in Patients with Hodgkin Lymphoma at ISHL 2018
Oct 25, 2018 04:02PM Seattle Genetics Reports Third Quarter 2018 Financial Results
Oct 8, 2018 06:51PM Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to be Presented at ESMO 2018 Congress
Oct 8, 2018 06:50PM Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress
Oct 3, 2018 08:00AM Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018
Oct 1, 2018 06:48AM Seattle Genetics (SGEN), Takeda Pharmaceutical Report Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin)
Oct 1, 2018 06:45AM Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Sep 21, 2018 10:48AM Seattle Genetics (SGEN) Announces ADCETRIS Approval in Japan for Frontline Hodgkin Lymphoma
Sep 21, 2018 10:48AM Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
Sep 4, 2018 08:00AM Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference
Jul 26, 2018 04:02PM Seattle Genetics Reports Second Quarter 2018 Financial Results
Jul 12, 2018 08:01AM Seattle Genetics (SGEN) Reports First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
Jul 12, 2018 08:00AM Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
Jul 11, 2018 08:02AM Seattle Genetics (SGEN) Reports Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer
Jul 11, 2018 08:00AM Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer
Jul 9, 2018 08:03AM Seattle Genetics (SGEN), Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Jul 9, 2018 08:00AM Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Jul 9, 2018 08:00AM Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Jun 28, 2018 08:00AM Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 26, 2018
Jun 13, 2018 08:04AM Seattle Genetics (SGEN) Reports First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin
Jun 13, 2018 08:00AM Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
Jun 6, 2018 08:00AM Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
Jun 4, 2018 09:09AM Seattle Genetics (SGEN) Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS in Newly Diagnosed Advanced HL at ASCO
Jun 4, 2018 09:00AM Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting
Jun 4, 2018 06:37AM Seattle Genetics (SGEN) & Astellas Update Phase 1 Data of Investigational Antibody-Drug Conjugate Enfortumab Vedotin
Jun 3, 2018 09:00AM Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
Jun 3, 2018 09:00AM Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
May 17, 2018 09:00AM Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer
May 17, 2018 08:05AM Seattle Genetics (SGEN) Announces Data Presentations at ASCO
May 17, 2018 08:00AM Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting
May 2, 2018 08:00AM Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
Apr 26, 2018 04:02PM Seattle Genetics Reports First Quarter 2018 Financial Results
Apr 12, 2018 08:09AM Seattle Genetics (SGEN) Announces Pre-Clinical & Clinical Data with ADCETRIS (brentuximab vedotin), ladiratuzumab vedotin, SGN-CD48A and SGN-2FF
Apr 12, 2018 08:00AM Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
Apr 5, 2018 08:00AM Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018
Mar 26, 2018 08:02AM Seattle Genetics (SGEN) & Astella Pharma Granted FDA Breakthrough Therapy Designation for Enfortumab Vedotin
Mar 26, 2018 08:00AM Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
View More Recent Stories View Older Stories